Healthcare Huddle
Topics
Drug Supply Chain

Drug Supply Chain

Exploring drug pricing, PBMs, and pharmacy roles in medication access.

Huddle Trends Medicine Inefficiency Insights Artificial Intellgience Public Health Residency Reflections Policy Drug Supply Chain Weight Management Sponsored Deep Dives Concepts Transitions of Care Insurance Digital Health Business

Amazon RxPass: Does a $5 Drug Subscription Improve Adherence?

Inefficiency Insights #67

Jared Dashevsky, MD

Jared Dashevsky, MD

Can Text Reminders Fix Medication Adherence? A New Study Says No—But AI Might

Inefficiency Insights #66

Jared Dashevsky, MD

Jared Dashevsky, MD

The 340B Drug Program: How Hospitals Profit While Patients Pay

Huddle #Trends

Jared Dashevsky, MD

Jared Dashevsky, MD

CMS Reveals 15 Drugs for Medicare Negotiation, Including Ozempic

Jared Dashevsky, MD

Jared Dashevsky, MD

Humira Biosimilars: Market Impact, Cost Savings, and Future Trends

Jared Dashevsky, MD

Jared Dashevsky, MD

Cost Plus Drugs Partnerships: Cutting Drug Costs for Health Systems

Jared Dashevsky, MD

Jared Dashevsky, MD

6 Practical Ways to Save on High U.S. Prescription Drug Costs

Inefficiency Insights #57

Jared Dashevsky, MD

Jared Dashevsky, MD

Curing Hepatitis C: The Netflix Model Explained

Jared Dashevsky, MD

Jared Dashevsky, MD

Why Are U.S. Drug Prices So High? Solutions for Lowering Costs

Huddle #Trends

Jared Dashevsky, MD

Jared Dashevsky, MD

CMS Negotiates Drug Prices: The Not-so-Clear Impact on Medicare Spending

Jared Dashevsky, MD

Jared Dashevsky, MD

A Comprehensive Analysis of Mark Cuban's Cost Plus Drugs Company

Huddle+ | Huddle #Trends

Jared Dashevsky, MD

Jared Dashevsky, MD

The Rise of Humira Biosimilars and the Battle for Market Share

Jared Dashevsky, MD

Jared Dashevsky, MD